Clinical Trials Browser

INDUSTRY × Hematologic Neoplasms × Alemtuzumab × Clear all

NCT00113048 2014-02-05

Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies

Phase 1 Terminated

Other hematologic neoplasm

Hematologic Neoplasms